On Monday, Verrica Pharmaceuticals Inc (NASDAQ: VRCA) was -10.28% drop from the session before settling in for the closing price of $0.58. A 52-week range for VRCA has been $0.38 – $8.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -5.46%. When this article was written, the company’s average yearly earnings per share was at 77.70%. With a float of $50.08 million, this company’s outstanding shares have now reached $91.79 million.
Considering the fact that the conglomerate employs 71 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 71.79%, operating margin of -772.39%, and the pretax margin is -919.21%.
Verrica Pharmaceuticals Inc (VRCA) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Verrica Pharmaceuticals Inc stocks. The insider ownership of Verrica Pharmaceuticals Inc is 45.85%, while institutional ownership is 31.92%. The most recent insider transaction that took place on Mar 17 ’25, was worth 2,805. In this transaction CHIEF LEGAL OFFICER of this company sold 4,315 shares at a rate of $0.65, taking the stock ownership to the 176,458 shares. Before that another transaction happened on Aug 26 ’24, when Company’s CHIEF LEGAL OFFICER sold 26,183 for $2.66, making the entire transaction worth $69,647. This insider now owns 115,303 shares in total.
Verrica Pharmaceuticals Inc (VRCA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 77.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 76.18% during the next five years compared to -5.46% drop over the previous five years of trading.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Trading Performance Indicators
You can see what Verrica Pharmaceuticals Inc (VRCA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.20, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.23 in one year’s time.
Technical Analysis of Verrica Pharmaceuticals Inc (VRCA)
Compared to the last year’s volume of 0.37 million, its volume of 0.91 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 19.83%.
During the past 100 days, Verrica Pharmaceuticals Inc’s (VRCA) raw stochastic average was set at 35.40%, which indicates a significant increase from 0.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.19% in the past 14 days, which was lower than the 115.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5472, while its 200-day Moving Average is $0.8450. Nevertheless, the first resistance level for the watch stands at $0.5616 in the near term. At $0.6006, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.6201. If the price goes on to break the first support level at $0.5031, it is likely to go to the next support level at $0.4836. Should the price break the second support level, the third support level stands at $0.4446.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Key Stats
There are 92,491K outstanding shares of the company, which has a market capitalization of 48.34 million. As of now, sales total 7,570 K while income totals -76,580 K. Its latest quarter income was 3,440 K while its last quarter net income were -9,740 K.
